CMS Will Weigh Three New Tech Assessments On Genetic Testing For Cancer
This article was originally published in The Gray Sheet
Two of the assessments are intended to inform an upcoming Medicare Evidence Development and Coverage Advisory Committee meeting.
You may also be interested in...
Breast cancer tests are the most common among the new genetic tests to emerge since 2011, an Agency for Healthcare Research and Quality report finds.
The industry’s angst is growing several months after CMS announced a plan to task contractors with independently setting regional payments for more than 100 new molecular diagnostic codes. A breakdown in the process so far, stakeholders say, could have a lasting impact on small, venture-backed labs.
Most of the 33 items or services in the list have implications for manufacturers of medical devices, combination products or diagnostics.